Karyopharm Therapeutics Revenue, Profits - KPTI Annual Income Statement

Add to My Stocks
$18.49 $0.08 (0.43%) KPTI stock closing price Sep 19, 2018 (Closing)

Financial statements provide us with a way to gain insights and undertake the fundamental analysis of a company. Checking Karyopharm Therapeutics stock price alone is not sufficient. The key financial statements of a company are the income statement, the balance sheet and the cash flow statement. The income statement is always for an accounting period, typically for a year or quarter, and affects the stock. In this case, the KPTI stock is bound to reflect the impact of the YOY growth of 0. Revenue for year 2017 is $1.6M and has increased from $- year on year as is evident when you compare the latest figures in the latest Karyopharm Therapeutics profit and loss statement with those of the prior corresponding period. Also see Karyopharm Therapeutics assets and Karyopharm Therapeutics free cash flow for a complete valuation of KPTI stock.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011
Karyopharm Therapeutics Revenues or Net Sales
1.6M------
Cost Of Goods Sold (COGS)-------
Karyopharm Therapeutics Gross Profit
1.6M------
Research & Development Expense107.27M86.93M97.74M60.12M28.45M14.09M8.62M
Selling General & Admin Expense24.87M23.94M21.58M15.94M5.88M2.42M1.84M
Income Before Depreciation Depletion Amortization-130.53M-110.73M-119.07M-75.84M-33.95M-15.89M-10.31M
Depreciation Depletion Amortization-------
Non Operating Income1.61M1.29M-----
Interest Expense-------
Karyopharm Therapeutics Pretax Income
-128.92M-109.43M-118.18M-75.77M-33.94M-15.88M-10.31M
Provision for Income Taxes-------
MinorityInterest-------
Investment Gains Losses-------
Other Income-------
Income Before Extraordinaries & Disc Operations-128.98M-109.57M-118.18M-75.77M-33.94M-15.88M-10.31M
Extraordinary Items & Discontinued Operations-------
Karyopharm Therapeutics Profit/ Loss (Net Income)
-128.98M-109.57M-118.18M-75.77M-33.94M-15.88M-10.31M
Average Shares used to compute Diluted EPS45.9M37.52M35.62M31.14M6.07M5.8M-
Average Shares used to compute Basic EPS45.9M37.52M35.62M31.14M6.07M5.8M-
Income Before Nonrecurring Items-128.98M-109.58M-118.18M-75.78M-33.95M-15.89M-
Income from Nonrecurring Items-------
Karyopharm Therapeutics Earnings Per Share Basic Net
-2.81-2.92-3.32-2.43-5.59-2.74-
Karyopharm Therapeutics Earnings Per Share Diluted Net
-2.81-2.92-3.32-2.43-5.59-2.74-
EPS Diluted Before Nonrecurring Items-2.81-2.92-3.32-2.43-5.59-2.74-
Preferred Dividends Acc Pd-------
Dividends Common-------
Dividend Per Share Common0.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Karyopharm Therapeutics stock analysis involves checking at least a few of the important things like:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: Karyopharm Therapeutics revenue chart implies that the company is growing. It has been the case with Karyopharm Therapeutics. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: The bottomline or the net income figure is arrived at by deducting all expenses from the topline which in this case is $-128.98M for KPTI stock. An improving bottomline implies that the company is growing its profits.

The income statement is also called statement of revenue and expense. The KPTI financials along with Karyopharm Therapeutics historical stock prices provide a lot of details about the firm.

Karyopharm Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
33.01
Dividend Yield
0%